Cerity Partners
TARA icon

Cerity Partners’s Protara Therapeutics TARA Stock Holding History

Cerity Partners’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66.4K Buy
+12,748
New +$75.5K ﹤0.01% 3071

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Cerity Partners's TARA Position: Q1 2026 in Review

Cerity Partners opened a new position in Protara Therapeutics (TARA) in Q1 2026: 12,748 shares worth $66.4K. The stake represents ﹤0.01% of the portfolio and ranks #3071 among its holdings.

114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • Cerity Partners held 12,748 shares of Protara Therapeutics worth $66.4K as of Q1 2026.
  • Protara Therapeutics was a new Cerity Partners position in Q1 2026.
  • Protara Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #3071 holding.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.